Galactose Treatment of a PGM1 Patient Presenting with Restrictive Cardiomyopathy

Overview

Journal JIMD Rep

Publisher Wiley

Date 2021 Jan 21

PMID 33473337

Citations 9

Authors

Sarah E Donoghue

Susan M White

Tiong Yang Tan

Remi Kowalski

Eva Morava

Joy Yaplito-Lee

Affiliations

Soon will be listed here.

Abstract

We report a patient diagnosed with PGM1-CDG at 11 years of age after two biallelic likely pathogenic variants in were found on research genomic sequencing. To our knowledge, he is the first patient with PGM1-CDG to be reported with a restrictive cardiomyopathy. Other clinical manifestations included cleft palate, asymptomatic elevated transaminases, intellectual disability and myopathy resulting in exercise intolerance. He was trialed on oral galactose therapy in increasing doses for 18 weeks to assess if there was any biochemical and clinical benefit. His galactose was continued for a further 9 months beyond the initial galactose treatment period due to improvements in exercise tolerance and myopathy. Treatment with galactose demonstrated an improvement in liver function and myopathy with improved exercise tolerance. Treatment with galactose for 15 months did not change heart function and exercise stress test results were stable.

Citing Articles

Transcriptome analysis reveals the role of long noncoding RNAs in specific deposition of inosine monphosphate in Jingyuan chickens.

Zhao W, Cai Z, Jiang Q, Zhang J, Yu B, Feng X J Anim Sci. 2024; 102.

PMID: 38738625 PMC: 11249926. DOI: 10.1093/jas/skae136.

Functional identification of in the regulating development and depositing of inosine monophosphate specific for myoblasts.

Zhao W, Cai Z, Wei C, Ma X, Yu B, Fu X Front Vet Sci. 2024; 10:1276582.

PMID: 38164393 PMC: 10758172. DOI: 10.3389/fvets.2023.1276582.

Metabolic Cardiomyopathies and Cardiac Defects in Inherited Disorders of Carbohydrate Metabolism: A Systematic Review.

Conte F, Sam J, Lefeber D, Passier R Int J Mol Sci. 2023; 24(10).

PMID: 37239976 PMC: 10218694. DOI: 10.3390/ijms24108632.

Successful heart transplantation in an infant with phosphoglucomutase 1 deficiency (PGM1-CDG).

Altassan R, Albert-Brotons D, Alowain M, Al-Halees Z, Jaeken J, Morava E JIMD Rep. 2023; 64(2):123-128.

PMID: 36873091 PMC: 9981415. DOI: 10.1002/jmd2.12350.

AAV-based gene therapy prevents and halts the progression of dilated cardiomyopathy in a mouse model of phosphoglucomutase 1 deficiency (PGM1-CDG).

Balakrishnan B, Altassan R, Budhraja R, Liou W, Lupo A, Bryant S Transl Res. 2023; 257:1-14.

PMID: 36709920 PMC: 10192047. DOI: 10.1016/j.trsl.2023.01.004.

References

Ondruskova N, Honzik T, Vondrackova A, Tesarova M, Zeman J, Hansikova H . Glycogen storage disease-like phenotype with central nervous system involvement in a PGM1-CDG patient. Neuro Endocrinol Lett. 2014; 35(2):137-41. View

Radenkovic S, Witters P, Morava E . Central nervous involvement is common in PGM1-CDG. Mol Genet Metab. 2018; 125(3):200-204. DOI: 10.1016/j.ymgme.2018.08.008. View

Stojkovic T, Vissing J, Petit F, Piraud M, Orngreen M, Andersen G . Muscle glycogenosis due to phosphoglucomutase 1 deficiency. N Engl J Med. 2009; 361(4):425-7. DOI: 10.1056/NEJMc0901158. View

Morava E . Galactose supplementation in phosphoglucomutase-1 deficiency; review and outlook for a novel treatable CDG. Mol Genet Metab. 2014; 112(4):275-9. PMC: 4180034. DOI: 10.1016/j.ymgme.2014.06.002. View

Voermans N, Preisler N, Madsen K, Janssen M, Kusters B, Abu Bakar N . PGM1 deficiency: Substrate use during exercise and effect of treatment with galactose. Neuromuscul Disord. 2017; 27(4):370-376. DOI: 10.1016/j.nmd.2017.01.014. View

Nolting K, Park J, Tegtmeyer L, Zuhlsdorf A, Gruneberg M, Rust S . Limitations of galactose therapy in phosphoglucomutase 1 deficiency. Mol Genet Metab Rep. 2017; 13:33-40. PMC: 5540825. DOI: 10.1016/j.ymgmr.2017.07.010. View

Tegtmeyer L, Rust S, van Scherpenzeel M, Ng B, Losfeld M, Timal S . Multiple phenotypes in phosphoglucomutase 1 deficiency. N Engl J Med. 2014; 370(6):533-42. PMC: 4373661. DOI: 10.1056/NEJMoa1206605. View

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405-24. PMC: 4544753. DOI: 10.1038/gim.2015.30. View

Thomson W, MACLAURIN J, Prineas J . Skeletal muscle glycogenosis: an investigation of two dissimilar cases. J Neurol Neurosurg Psychiatry. 1963; 26:60-8. PMC: 495536. DOI: 10.1136/jnnp.26.1.60. View

10.

Donoghue S, White S, Tan T, Kowalski R, Morava E, Yaplito-Lee J . Galactose treatment of a PGM1 patient presenting with restrictive cardiomyopathy. JIMD Rep. 2021; 57(1):29-37. PMC: 7802629. DOI: 10.1002/jmd2.12177. View

11.

Fernlund E, Andersson O, Ellegard R, Klang Arstrand H, Green H, Olsson H . The congenital disorder of glycosylation in PGM1 (PGM1-CDG) can cause severe cardiomyopathy and unexpected sudden cardiac death in childhood. Forensic Sci Int Genet. 2019; 43:102111. DOI: 10.1016/j.fsigen.2019.06.012. View

12.

Zeevaert R, Scalais E, Mosquera L, De Meirleir L, de Beaufort C, Witsch M . PGM1 deficiency diagnosed during an endocrine work-up of low IGF-1 mediated growth failure. Acta Clin Belg. 2016; 71(6):435-437. DOI: 10.1080/17843286.2016.1142043. View

13.

Yan-Wai Wong S, Gadomski T, van Scherpenzeel M, Honzik T, Hansikova H, Brocke Holmefjord K . Oral D-galactose supplementation in PGM1-CDG. Genet Med. 2017; 19(11):1226-1235. PMC: 5675745. DOI: 10.1038/gim.2017.41. View

14.

Yan-Wai Wong S, Beamer L, Gadomski T, Honzik T, Mohamed M, Wortmann S . Defining the Phenotype and Assessing Severity in Phosphoglucomutase-1 Deficiency. J Pediatr. 2016; 175:130-136.e8. DOI: 10.1016/j.jpeds.2016.04.021. View

15.

Timal S, Hoischen A, Lehle L, Adamowicz M, Huijben K, Sykut-Cegielska J . Gene identification in the congenital disorders of glycosylation type I by whole-exome sequencing. Hum Mol Genet. 2012; 21(19):4151-61. DOI: 10.1093/hmg/dds123. View

16.

Loewenthal N, Haim A, Parvari R, Hershkovitz E . Phosphoglucomutase-1 deficiency: Intrafamilial clinical variability and common secondary adrenal insufficiency. Am J Med Genet A. 2016; 167A(12):3139-43. DOI: 10.1002/ajmg.a.37294. View

17.

Tan T, Gonzaga-Jauregui C, Bhoj E, Strauss K, Brigatti K, Puffenberger E . Monoallelic BMP2 Variants Predicted to Result in Haploinsufficiency Cause Craniofacial, Skeletal, and Cardiac Features Overlapping Those of 20p12 Deletions. Am J Hum Genet. 2017; 101(6):985-994. PMC: 5812889. DOI: 10.1016/j.ajhg.2017.10.006. View